Phase 2 N=31 Study of ADI-PEG 20 in Patients With Advanced Melanoma
Metastatic Melanoma · Skin Cancer · Neoplasm
Primary: Assessment of Safety and Tolerability of ADI-PEG 20 — 6; 6; 19; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=90 Hormonal Factors in the Treatment of Anorexia Nervosa
Anorexia Nervosa · Eating Disorder · Anxiety
Primary: Change From Baseline in Weight — 0.1; 1.5 kilograms
N/A N=26 Effect of Increased Free Fatty Acids on Leptin Function
Obesity · Leptin Resistance
Primary: Change in Circulating Glucagon-like Peptide-1 (GLP-1) Levels — 7147; 11725; 11898; 28060 pM*min
Phase 3 N=2,334 Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Overall Survival — 29.0; 30.0 months — p=0.08
N/A N=240 The Effectiveness of a Decision-Support Tool for Adult Consumers With Mental Health Needs and Their Care Managers
Mental Disorders
Primary: Short Form Health Survey-12 (SF-12), Physical Symptoms Subscale — 38.167; 38.601; 37.187; 37.108 units on a scale — p=.0679
N/A N=49 FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates
Pulmonary Infiltrate New
Primary: Number of Patients With Positive Culture or Molecular Results After Brochoscopy — 40 participants
Phase 2 N=122 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: FEV1 AUC 0-12 on Day 7 — 1.537; 1.529; 1.429; 1.434 Liters
Phase 3 N=231 Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
Neurotoxicity · Pain · Peripheral Neuropathy
Primary: Change in Average Pain From Week 1 to Week 5, as Measured by the BPI-SF Average Pain Severity Item — 1.06; 0.34 units on a scale — p=0.003
Phase 3 N=463 Smoking Cessation for American Indians
Smoking Cessation
Primary: 7-Day Point Prevalence Abstinence From Smoking for 6 Months — 49; 26; 26; 15 Participants
N/A N=403 Drug Use Investigation Of Azithromycin IV For Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)
Pneumonia · Pelvic Inflammatory Disease
Primary: Number of Participants With Treatment-Related Adverse Events — 39; 7 Participants
Phase 2 N=68 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)
Pulmonary Tuberculosis
Primary: Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time…
N/A N=28 Does Cold Provocation Increase Brown Adipose Tissue Volume?
Brown Adipose Tissue, Human
Primary: Brown Adipose Tissue, Absolute Volume — 0.0066; 0.0021 liters
Phase 2 N=35 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
Recurrent Thyroid Cancer · Stage IVA Follicular Thyroid Cancer · Stage IVA Papillary Thyroid Cancer
Primary: Overall Response Rate — 11 Participants
N/A N=100 Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures
Deep Vein Thrombosis
Primary: Number of Participants With Post-operative Ultrasound Without Evidence of Thromboembolism — 91 Participants
Phase 3 N=56 Add on Lacosamide Versus High Dose Monotherapy
Epilepsy
Primary: Percentage of Participants Achieving Six Month Seizure Freedom — 47.4; 41.7 percentage of participants — p=0.49